Probiotics, psychobiotics, and postbiotics: a therapeutic modality for the management of schizophrenia.

IF 3.6 4区 医学 Q2 NEUROSCIENCES
Sumel Ashique, Debasmita Paul, Biplab Debnath, Dinesh Kumar Chellappan, Joy Das, Utpal Bhui, Mohhammad Ramzan, Neha Sharma, Bimlesh Kumar, Sathvik Belagodu Sridhar, Uttam Prasad Panigrahy, Md Sadique Hussain
{"title":"Probiotics, psychobiotics, and postbiotics: a therapeutic modality for the management of schizophrenia.","authors":"Sumel Ashique, Debasmita Paul, Biplab Debnath, Dinesh Kumar Chellappan, Joy Das, Utpal Bhui, Mohhammad Ramzan, Neha Sharma, Bimlesh Kumar, Sathvik Belagodu Sridhar, Uttam Prasad Panigrahy, Md Sadique Hussain","doi":"10.1080/1028415X.2025.2560658","DOIUrl":null,"url":null,"abstract":"<p><p>Schizophrenia is a debilitating, chronic neuropsychiatric disorder, a multifactorial disorder combining genetic, neurodevelopmental, immunological, and environmental factors. Common antipsychotic treatments may be effective against positive symptoms, but still lack when dealing with negative symptoms, cognitive defects, and side effects of medication. Recent innovations show how the gut-brain axis is an important modulator of neuropsychiatric health, identifying microbial dysbiosis as a cause of schizophrenia. This review examines the therapeutic potential of such treatments of probiotics, psychobiots, and postbiotics as an adjunctive or alternative treatment targeting the way of modulating neuroinflammation, neurotransmitter synthesis, experience, and maintenance of blood-brain barrier integrity. Probiotics, which are live beneficial microbes, have immunomodulatory and neuroactive effects; psychobiotics, a subclass that has specific mental effects, modify stress-response systems and neurotrophic factors. Postbiotics, consisting in turn of microbial metabolism like short-chain fatty acids, present improved safety and stability with anti-inflammatory and antioxidant functions. Available clinical and preclinical evidence suggests the ability of these agents to attenuate the symptoms of schizophrenia and cognitive impairment, as well as to increase the tolerability of treatment. Regarding the conclusive presumptions, however, strain-specific variability and inconsistent methodologies confined by the sparse large-scale trials limit them. New technologies of nanocarrier systems, artificial intelligence, and personalized microbiome profiling might provide the best precision of the therapy. In this review, pitfalls in mechanistic insights, progress reports on translational studies, and future research prospects are deconstructively examined to support microbiota-based interventions as promising paradigms of holistic schizophrenia management.</p>","PeriodicalId":19423,"journal":{"name":"Nutritional Neuroscience","volume":" ","pages":"1-27"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutritional Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1028415X.2025.2560658","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Schizophrenia is a debilitating, chronic neuropsychiatric disorder, a multifactorial disorder combining genetic, neurodevelopmental, immunological, and environmental factors. Common antipsychotic treatments may be effective against positive symptoms, but still lack when dealing with negative symptoms, cognitive defects, and side effects of medication. Recent innovations show how the gut-brain axis is an important modulator of neuropsychiatric health, identifying microbial dysbiosis as a cause of schizophrenia. This review examines the therapeutic potential of such treatments of probiotics, psychobiots, and postbiotics as an adjunctive or alternative treatment targeting the way of modulating neuroinflammation, neurotransmitter synthesis, experience, and maintenance of blood-brain barrier integrity. Probiotics, which are live beneficial microbes, have immunomodulatory and neuroactive effects; psychobiotics, a subclass that has specific mental effects, modify stress-response systems and neurotrophic factors. Postbiotics, consisting in turn of microbial metabolism like short-chain fatty acids, present improved safety and stability with anti-inflammatory and antioxidant functions. Available clinical and preclinical evidence suggests the ability of these agents to attenuate the symptoms of schizophrenia and cognitive impairment, as well as to increase the tolerability of treatment. Regarding the conclusive presumptions, however, strain-specific variability and inconsistent methodologies confined by the sparse large-scale trials limit them. New technologies of nanocarrier systems, artificial intelligence, and personalized microbiome profiling might provide the best precision of the therapy. In this review, pitfalls in mechanistic insights, progress reports on translational studies, and future research prospects are deconstructively examined to support microbiota-based interventions as promising paradigms of holistic schizophrenia management.

益生菌、精神生物制剂和后生物制剂:一种治疗精神分裂症的方法。
精神分裂症是一种使人衰弱的慢性神经精神疾病,是一种多因素疾病,结合了遗传、神经发育、免疫和环境因素。常见的抗精神病药物治疗可能对阳性症状有效,但在处理阴性症状、认知缺陷和药物副作用时仍然缺乏。最近的创新表明肠脑轴是神经精神健康的重要调节因子,确定微生物生态失调是精神分裂症的一个原因。本文综述了益生菌、精神生物制剂和后生物制剂作为辅助或替代治疗的治疗潜力,这些治疗针对调节神经炎症、神经递质合成、经验和维持血脑屏障完整性的方式。益生菌是一种活的有益微生物,具有免疫调节和神经活性作用;精神生成素是一类具有特定精神效应的药物,可改变应激反应系统和神经营养因子。后生物制剂,由微生物代谢组成,如短链脂肪酸,具有更好的安全性和稳定性,具有抗炎和抗氧化功能。现有的临床和临床前证据表明,这些药物能够减轻精神分裂症和认知障碍的症状,并增加治疗的耐受性。然而,对于结论性的假设,菌株特异性的可变性和受稀疏的大规模试验限制的不一致的方法限制了它们。纳米载体系统、人工智能和个性化微生物组分析的新技术可能提供最佳的治疗精度。在这篇综述中,解构性地考察了机制见解中的缺陷、转化研究的进展报告和未来的研究前景,以支持基于微生物群的干预作为整体精神分裂症管理的有前途的范例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nutritional Neuroscience
Nutritional Neuroscience 医学-神经科学
CiteScore
8.50
自引率
2.80%
发文量
236
审稿时长
>12 weeks
期刊介绍: Nutritional Neuroscience is an international, interdisciplinary broad-based, online journal for reporting both basic and clinical research in the field of nutrition that relates to the central and peripheral nervous system. Studies may include the role of different components of normal diet (protein, carbohydrate, fat, moderate use of alcohol, etc.), dietary supplements (minerals, vitamins, hormones, herbs, etc.), and food additives (artificial flavours, colours, sweeteners, etc.) on neurochemistry, neurobiology, and behavioural biology of all vertebrate and invertebrate organisms. Ideally this journal will serve as a forum for neuroscientists, nutritionists, neurologists, psychiatrists, and those interested in preventive medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信